What is Veradermics?
Veradermics is a biopharmaceutical firm operating in the clinical-stage of development, focused on pioneering novel, non-hormonal therapeutic solutions for a range of dermatologic and aesthetic concerns. The company's primary focus is on advancing oral therapies designed to address hair regrowth, a significant market within the dermatology sector. This strategic direction positions Veradermics to potentially disrupt existing treatment paradigms by offering differentiated, non-hormonal alternatives.
How much funding has Veradermics raised?
Veradermics has raised a total of $616.3M across 4 funding rounds:
Series B
$75M
Series C
$150M
Private Equity
$135M
IPO
$256.3M
Series B (2024): $75M with participation from Osage University Partners, PhiFund Ventures, Surveyor Capital, J.W. Childs Associates, Suvretta Capital Management, Longitude Capital, and Connecticut Innovations
Series C (2025): $150M led by Invus, Longitude Capital, Viking Global Investors, Suvretta Capital Management, Marshall Wace, Infinitium, SR One, LifeSci Venture Partners, and Columbia Threadneedle Investments US
Private Equity (2025): $135M, investors not publicly disclosed
IPO (2026): $256.3M featuring Lilly and Wellington Management
Key Investors in Veradermics
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Wellington Management
Wellington Management Company, LLP is a global, independent investment management firm based in Boston, Massachusetts. It provides institutional clients with portfolio management, research, and tailored investment solutions across equities, fixed income, multi-asset, and alternative strategies.
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
What's next for Veradermics?
With the recent major strategic investment and a history of significant capital raises, Veradermics is poised for accelerated growth and the advancement of its lead programs through clinical trials and towards commercialization. The substantial enterprise-level funding suggests a strong investor confidence in the company's technology and market potential. Future endeavors will likely concentrate on expanding its pipeline, navigating regulatory pathways, and establishing robust manufacturing and distribution channels to meet anticipated market demand for its innovative dermatologic treatments.
See full Veradermics company page
